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Abstract
Background: Few randomised studies have compared antiandrogen intermittent hormonal therapy
(IHT)with continuousmaximal androgen blockade (MAB) therapy for advanced prostate cancer (PCa).
Objective: To determine whether overall survival (OS) on IHT (cyproterone acetate; CPA) is non-
inferior to OS on continuous MAB.
Design, setting, and participants: This phase 3 randomised trial compared IHT and continuous MAB
in patients with locally advanced or metastatic PCa.
Intervention: During induction, patients received CPA 200 mg/d for 2 wk and then monthly depot
injections of a luteinising hormone-releasing hormone (LHRH; triptoreline 11.25 mg) analogue plus
CPA 200 mg/d. Patients whose prostate-speciﬁc antigen (PSA) was <4 ng/ml after 3 mo of induction
treatment were randomised to the IHT arm (stopped treatment and restarted on CPA 300 mg/d
monotherapy if PSA rose to 20 ng/ml or they were symptomatic) or the continuous arm (CPA
200 mg/d plus monthly LHRH analogue).
Outcomemeasurements and statistical analysis: Primary outcomemeasurement was OS. Secondary
outcomes included cause-speciﬁc survival, time to subjective or objective progression, and quality of
life. Time off therapy in the intermittent arm was recorded.
Results and limitations: Werecruited1045patients, ofwhich918 responded to induction therapyand
were randomised (462 to IHT and 456 to continuousMAB). OS was similar between groups (p = 0.25),
and noninferiority of IHT was demonstrated (hazard ratio [HR]: 0.90; 95% conﬁdence interval [CI],
0.76–1.07). There was a trend for an interaction between PSA and treatment (p = 0.05), favouring IHT
over continuous therapy in patientswith PSA1ng/ml (HR: 0.79; 95% CI, 0.61–1.02).Men treatedwith
IHT reported better sexual function. Among the 462 patients on IHT, 50% and 28% of patients were off
therapy for2.5 yr or>5 yr, respectively, after randomisation. Themain limitation is that the length of
time for the trial to mature means that other therapies are now available. A second limitation is that
T3 patients may now proﬁt from watchful waiting instead of androgen-deprivation therapy.
Conclusions: Noninferiority of IHT in terms of survival and its association with better sexual activity
y su
peathan continuous therap
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Prostate cancer (PCa) is one of the most commonly
diagnosed cancers in men [1]. Incidence in recent years
has been increasing worldwide and is expected to continue
with the current ageing population; this increase poses a
global major health and economic burden on society.
Intermittent hormonal therapy (IHT) with antiandrogens
is used increasingly to improve the quality of life (QoL) of
PCa patients without diminishing the efficacy of chronic
androgen-deprivation therapy (ADT). ADT is the current
standard therapy for advanced PCa or cancer that has
metastasised beyond the prostate. To maximise the efficacy
and tolerability of ADT while reducing adverse events, it is
possible for some patients to alternate treatment and off-
treatment periods.
Few randomised studies have compared the efficacy of
IHT with continuous therapy; however, available data
suggest that IHT is at least as effective as continuous
treatment in the management of advanced PCa with regard
to both disease progression and overall survival (OS) [2–5].
Further potential benefits of IHT include reduced side-
effects compared with continuous therapy, improved QoL
(especially recovery of sexual potency), health care cost
savings, and delayed emergence of hormonal refractoriness
[6–8]. However, no randomised studies to date have
assessed IHT delivered as monotherapy with antiandrogens
(cyproterone acetate; CPA).
This study aimed to demonstrate the noninferiority of
antiandrogen monotherapy with CPA IHT compared with
continuous maximal androgen blockade (MAB) therapy.
The European Association of Urology recently ac-
knowledged that intermittent ADT (IADT) is already
offered to patients with advanced PCa and stated in its
guidelines that IADT should no longer be considered
experimental [1].
2. Patients and methods
South European Uroncological Group (SEUG) 9901, a phase 3 random-
ised trial, compared intermittent and continuous androgen suppression
with respect to OS, time to loss of androgen dependence, symptom-free
survival, and QoL. Patients were recruited in 31 centres in Portugal,
Spain, Italy, Turkey, Greece, Slovakia, and the United Kingdom. All
patients gave informed consent. The study opened in September 1999,
with the ﬁrst patient randomised in January 2000 and the last patient
randomised in September 2007. Follow-up for this analysis ceased in
October 2012.
2.1. Patients
Inclusion criteria were histologically conﬁrmed prostate adenocarcino-
ma, cT3–cT4M0 andM1, serumprostate-speciﬁc antigen (PSA)4 ng/ml
and 100 ng/ml, age 80 yr, World Health Organisation performance
status 0–2, and normal liver function not suitable for deﬁnitive
treatment. Exclusion criteria were previous hormonal therapy or
chemotherapy, presence of another neoplasm (except skin, excluding
melanoma), severe concomitant chronic disease, or expected follow-up
difﬁculties. Prior surgery and radiotherapy were reasons for exclusion.
Clinical stage was assessed by the investigator in each centre, and there
was no central pathology review.2.2. Intervention
All patients received induction therapy of CPA 200 mg/d for 2 wk,
followed bymonthly depot injections of a luteinising hormone-releasing
hormone (LHRH) agonist (triptoreline 11.25 mg) plus CPA 200 mg/d.
Patients whose PSA levels decreased to <4 ng/ml 14 wk after starting
induction therapy were randomised to receive either IHT or continuous
antiandrogen therapy. Patients randomised to the continuous arm
received CPA 200 mg/d plus monthly LHRH agonist, whereas those
randomised to the IHT arm ceased treatment. Monotherapy with CPA
300 mg/d was restarted in the IHT arm if the PSA level rose to20 ng/ml
or if the patient experienced symptoms attributable to PCa.
Patients in both arms discontinued when there was evidence of
objective progression (distant metastases or new metastatic sites) or
subjective progression. Subjective progression was deﬁned as the
presence of at least two of the following three criteria: (1) biochemical
progression, deﬁned as an increase of the PSA level by 20% on two
successive occasions at least 1 mo apart; (2) an increase in pain by two
increments; or (3) worsening of performance status by two increments.
QoL was assessed every 6 mo and in the intermittent arm when therapy
was restarted, using the European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30 questionnaire and the Prostate
Cancer Module.
2.3. Statistical analysis
The primary aim of the study was to demonstrate noninferiority of
intermittent CPA therapy compared with continuous MAB in terms of
OS. For continuous therapy, it was assumed thatM0 andM1 patients had
median survival of 5 yr and 2.9 yr, respectively. Assuming that
approximately 65% and 35% of patients would have been M0 and M1,
respectively, then the median survival time for the entire group of
patients on continuous MAB was expected to be approximately 4.25 yr.
Intermittent CPA therapywas considered to be noninferior to continuous
MAB if median survival was no worse than 3.5 yr, which corresponds to
an increase of 20% in the hazard ratio (HR; 1.21). Based on a one-sided
log-rank test for noninferiority at error rates a = 0.05 and b = 0.20, a total
of 658 deaths were required for statistical analysis. With an entry rate of
150 patients per year and a follow-up period of 5 yr after the last patient
had been entered, randomisation of 900 patients over 6 yr was planned.
Statistical analysis was carried out using R v.2.15 (R Foundation,
Vienna, Austria). Chi-square tests were used to test the association
between treatment and the percentage of patients with side effects.
Kaplan-Meier curves were used to estimate the time to death and
progression-free survival (PFS) and were compared using the two-sided
log-rank test and a Cox proportional hazardsmodel.Median survival was
estimated from the Kaplan-Meier curve. HRs were expressed as
intermittent therapy compared with continuous therapy, and a 95%
conﬁdence interval (CI) was used. The null hypothesis (HR: 1.21;
specifying noninferiority) versus the alternative (HR: 1) was used for the
main outcome of OS and a one-sided test. Cox regression models were
used to account for the effect of prognostic factors. Cause-speciﬁc deaths
were analysed by assessing competing risks [9,10] using the cmprsk
library in R v.2.2-2 (R Foundation, Vienna, Austria). Mixed-effect
regression models were used to investigate the trends in PSA and QoL
scores during the course of the study. Results are reported at the
5% signiﬁcance level, and 95% CIs are used for all estimated effects.
The Benjamini and Hochberg procedure [16] was used to adjust for
multiple testing of the subscores in the QoL analysis.
3. Results
In total, 1045 patients were recruited and 918 patients
were randomised, 462 to IHT and 456 to continuous
Table 1 – Patient characteristics at randomisation
Intermittent Continuous
n % n %
Total 462 – 456 –
Age group
<65 yr 58 12.6 52 11.4
65–69 yr 72 15.6 83 18.2
70–74 yr 152 32.9 154 33.8
75–79 yr 157 34.0 149 32.7
80 yr 23 5.0 18 3.9
WHO performance status
0 419 90.7 413 90.6
1 38 8.2 36 7.9
2 2 0.4 6 1.3
Tumour stage
T2 15 3.2 20 4.4
T3 416 90.0 417 91.4
T4 31 6.7 19 4.2
Histology
Biopsy 440 95.2 440 96.5
TUR 20 4.3 16 3.5
Not available 2 0.4 0 0
Tumour grade
G1 23 5.0 25 5.5
G2 314 68.0 322 70.6
G3/X 125 27.1 109 23.9
Gleason score
2–4 28 6.1 24 5.3
5–6 186 40.3 170 37.3
7–8 223 48.3 235 51.5
9 25 5.4 27 5.9
Bone scan
Normal 355 76.8 343 75.2
1–6 hot spots 42 9.1 43 9.4
6 hot spots 7 1.5 2 0.4
Other abnormalities 39 8.4 46 10.1
Not carried out 19 4.1 22 4.8
Metastatic status
M0 410 88.7 406 89
M1 52 11.3 50 11
Associated chronic disease*
Any 122 28.4 121 28.4
MI 22 4.8 24 5.3
DVT 8 1.7 3 0.7
CVA 21 4.5 18 3.9
Respiratory 24 5.2 21 4.6
Other 2 0.4 2 0.4
OACD 70 15.2 70 15.4
PSA level
<1 ng/ml 229 49.6 242 53.1
1–2 ng/ml 102 22.1 74 16.2
>2–4 ng/ml 131 28.4 140 30.7
CVA = cerebral vascular accident; DVT = deep vein thrombosis; MI = myocardial infarction; PSA = prostate-speciﬁc antigen; TUR = transurethral resection;
WHO =World Health Organisation.
* Patients may have more than one chronic disease; two ineligible patients were randomised who had T2M0.
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tion are shown in Table 1. The patient distribution was
similar in the two treatment groups (Table 1). The median
PSA level at recruitment (before induction therapy) of
patients that were subsequently randomised was 15 ng/ml
and then 1.4 ng/ml after the induction period, with 31%
having PSA 0.5 ng/ml. PSA level, Gleason score, and
metastatic status at baseline were the only independent
predictors of PSA level at randomisation; T stage, tumour
grade, and age had no effect. PSA level at randomisationincreasedwithhigher baselineGleason scores: Gleason score
2–4, median PSA level 0.6 ng/ml; Gleason score 5–6, median
PSA level 0.7 ng/ml; Gleason score 7–8, median PSA level
1.2 ng/ml; Gleason score 9–10, median PSA level 1.6 ng/ml
( p< 0.001).
The median follow-up time from randomisation was
66 mo (maximum: 12 yr), and 56% of patients were
observed for >5 yr; 393 patients were alive at the last
follow-up. Progression was reported in 299 patients, 168 in
the IHT arm and 131 in the continuous arm (Table 2).
Table 2 – Patients alive, lost to follow-up, dead, with cause of death and progression by treatment arm
Intermittent
treatment
Continuous
treatment
95% CI p
n % n % HR Lower Upper –
Randomised 462 – 456 – – – – –
Alive at last contact 204 44.2 189 41.4 – – – –
Lost to follow-up 11 2.4 11 2.4 – – – –
Any progression 168 36.4 131 28.7 1.16 0.93 1.47 0.195
Dead 258 55.8 267 58.6 0.90 0.76 1.07 0.252
Cancer 103 22.3 96 21.1 1.00 0.76 1.32 0.995
Prostate cancer 82 17.7 82 18 0.93 0.69 1.26 0.648
Second primary 21 4.5 14 3.1 1.41 0.71 2.75 0.332
Cardiovascular death 107 23.2 122 26.8 0.83 0.64 1.07 0.152
Other/unknown 48 10.4 49 10.7 0.91 0.61 1.36 0.650
CI = conﬁdence interval; HR = hazard ratio.
HRs for intermittent therapy compared with continuous therapy and 95% CIs from a Cox regression model.
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there were slightly more progressions among those on IHT
(HR: 1.16; 95% CI, 0.93–1.47; p = 0.20).
Overall, 525 patients died, 258 in the IHT arm and 267 in
the continuous arm. There was no significant difference in
OS on intermittent therapy (HR: 0.90; 95% CI, 0.76–1.07;
p = 0.99 [one-sided test]) (Table 2, Fig. 1). The upper 95%
confidence limit is less than the 1.21 limit specified in the
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Fig. 1 – Kaplan-Meier curves for the time to any progression and time to death. T
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Table 3 – Hazard ratios (HR) and 95% confidence intervals (lower and upper) from (a) the cox model for progression free survival and (b) the
competing risks model for the cause of death
(a) Model for progression free survival
95% CI
HR Lower Upper p
Continuous 1.00
Intermittent 1.02 0.87 1.20 0.8291
M0 1.00
M1 1.66 1.29 2.12 0.0001
Age <60 1.00
Age 60–69 0.74 0.49 1.10 0.1305
Age 70–74 0.88 0.60 1.31 0.5362
Age 75+ 1.25 0.84 1.85 0.2702
PSA 0–0.5 1.00
PSA 0.5–1 1.26 0.98 1.61 0.0703
PSA 1–2 1.41 1.11 1.80 0.0050
PSA 2–4 2.06 1.66 2.54 0.0000
Gleason 2–4 1.00
Gleason 5–6 1.43 0.78 2.65 0.2478
Gleason 7–8 1.94 1.07 3.50 0.0285
Gleason 9+ 1.83 0.88 3.81 0.1086
(b) Competing risks model for cause of death
PCa OMD CVD Other
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
– Lower Upper – Lower Upper – Lower Upper – Lower Upper
Unadjusted
Continuous 1 – – 1 – – 1 – – 1 – –
Intermittent 0.98 0.72 1.33 1.49 0.76 2.94 0.83 0.65 1.08 0.97 0.65 1.45
Adjusted
Continuous 1 – – 1 – – 1 – – 1 – –
Intermittent 1.02 0.75 1.39 1.46 0.75 2.87 0.82 0.64 1.06 0.98 0.66 1.47
M0 1 – – – – – – – – – – –
M1 3.29 2.28 4.73 1.23 0.43 3.48 0.63 0.38 1.03 0.81 0.40 1.63
PSA <1 ng/ml 1 – – – – – – – – – – –
PSA 1–2 ng/ml 1.10 0.70 1.72 0.98 0.44 2.20 1.51 1.09 2.09 0.79 0.45 1.41
PSA >2–4 ng/ml 2.12 1.50 2.99 0.40 0.15 1.07 1.39 1.02 1.88 1.07 0.68 1.68
CI = conﬁdence interval; CVD = cardiovascular disease; HR = hazard ratio; OMD = othermetastatic disease (second primary); PCa = prostate cancer; PSA = prostate-
speciﬁc antigen.
Table 4 – Patients reporting specified side effects at least once
during follow-up by treatment arm
Intermittent
treatment
Continuous
treatment
p*
No. of patients** 436 421 –
Side effect
Hot ﬂushes 8.3 24.9 <0.0001
Gynaecomastia 13.8 37.3 <0.0001
Headache 8.0 15.9 0.0005
Skin complaints 0.7 1.7 0.3124
Other 11.0 12.8 0.4741
* x2 test of the difference between the percentages.
** Number of patients with at least one follow-up form completed.
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 2 3 2 – 2 3 9236Another 69 patients, 25 on continuous therapy and 44 on
IHT, progressed but were still alive at the time the analysis
took place. There was no evidence of any difference
between continuous therapy and IHT in terms of PFS
(HR: 1.01; 95% CI, 0.86–1.19; p = 0.89). Metastatic status,
age, PSA, and Gleason score were all independently
associated with PFS (Table 3a).
The number of deaths due to any cancer, PCa, second
primary cancer/other malignant disease (OMD), cardiovas-
cular death (CVD), and other/unknown causes were similar
between treatment arms (Table 2). The competing risks
analysis showed that the slightly reduced hazard of dying in
the group on IHT resulted primarily from fewer deaths from
CVD balanced by an increased risk of death from a second
primary cancer (Table 3b). None of these differences in HR
was statistically significant (Table 3b).
Both metastatic status and PSA level at randomisation
were associated with death from PCa but not with OMD or
other causes of death (Table 3b). Adjusting for metastatic
status and PSA at randomisation, the HR of dying from one
of the four causes was similar to the unadjusted values.3.1. Safety and quality of life
Side effectswere generally reportedmore frequently among
patients on continuous therapy (Table 4). Summary QLQ-
C30 totals were similar between study arms (2.1 points
Table 5 – Patients and median times on and off therapy (weeks) in the intermittent arm according to prostate-specific antigen level at
randomisation
All patients PSA <1 ng/ml PSA 1–4 ng/ml
n Time, median, wk n Time, median, wk n Time, median, wk
Randomisation to ﬁrst time on therapy 454 132.0 224 162.0 230 110.0
Duration of time on ﬁrst therapy 231 20.0 110 16.7 121 26.0
Duration of second off-therapy period 165 43.0 95 49.6 70 33.1
Duration of time on second therapy 121 19.6 75 18.1 46 21.1
PSA = prostate-speciﬁc antigen.
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continuous arm compared with the intermittent arm;
p = 0.11) during 60 mo of follow-up. QLQ-C30 scores
decreased in both arms, from 83.4 (SE: 1.96) at baseline
to 70.5 (SE: 0.96) after 60mo, and the gradient of the decline
was similar in the two arms ( p = 0.94). During follow-up,
the only differences between the two groups of patients
were in relation to the symptoms and sexual activity
questions in the EORTC Prostate Cancer Module, with a
significantly higher proportion of patients in the continuous
arm reporting symptoms of hot flushes, gynaecomastia and
swelling of the legs ( p = 0.0001), and sexual problems
( p = 0.003). Reported sexual activity decreased in both
arms during the study, although sexual activity was
significantly greater (p < 0.0001) in the IHT arm. Shortly
after randomisation, with themajority of patients in the IHT
arm off therapy, the level of sexual activity after 6mo in this
group was similar to pretreatment levels (31.3% and 32.7%,
respectively); sexual activity then decreased as progres-
sively more patients in the IHT arm received CPA therapy.
However, at 30 mo after randomisation, the proportion
of patients reporting sexual activity was significantly
greater in the IHT arm than in the continuous arm (24.9%
of 226 patients vs 6.4% of 145 patients, respectively;
p < 0.0001).
Among the 462 patients randomised to IHT, 50%were off
therapy for at least 2.5 yr following randomisation (Table 5)
and 28% were off-therapy for >5 yr. The median time off
therapy for patients whose PSA levels were 1 ng/ml and
1–4 ng/ml was 3.1 yr and 2.1 yr, respectively (Table 5).
Patients returning to therapy had a median of 20 wk of
treatment (16.7 wk and 26 wk for those with PSA levels
<1ng/ml and1–4ng/ml, respectively),whichwas followed
by a second period off therapy (Table 5). Only 121 of
patients on IHT had two returns to therapy postrandomi-
sation, and this was for a median of 19.6 wk (Table 5).
4. Discussion
Two observations have considerable clinical importance:
(1) a 3-mo period of induction therapy was used in this
study, as in SEUG 9401 [2], and (2) patients in the
intermittent arm who were on therapy received CPA
300 mg/d as monotherapy. This intermittent protocol is
the first using antiandrogen monotherapy, and the study
demonstrated that intermittent monotherapy with CPA300 mg/dwas noninferior to continuous therapy in terms of
OS. Indeed, the hazard of dying on intermittent therapywas
20% lower than on continuous therapy in patients with a
PSA level 1 ng/ml after induction therapy.
The study is reporting early in terms of numbers of
deaths, as all randomised patients had been followed for at
least 5 yr. The death rate was lower than anticipated, and
the estimated proportion of patients surviving at 5 yr was
61%, with a median survival time of 6.6 yr compared with
the anticipated 4.5 yr. By October 2012, there were 525
deaths and 106 deaths were accumulated over the last 2 yr
follow-up. Thus a further 2 yr follow-up, at least, would be
needed to accrue the additional 133 deaths required to
reach the 658 deaths specified in the protocol. In addition,
noninferiority of intermittent therapy compared with
continuous therapy was demonstrated in terms of OS.
Therewas also no evidence of any difference in terms of PFS,
and with an HR of 1.01 (95% CI, 0.86–1.19), it is clear that
noninferiority of IHT compared with continuous therapy
can also be demonstrated for PFS. Metastatic status, PSA
level at randomisation, Gleason score, and age were
independent predictors of PFS, with age 60–74 yr, M0,
low Gleason score, and low PSA associated with longer
duration of PFS.
In this study, 50% of patients receiving IHT were off
therapy for at least 2.5 yr following initial LHRH therapy,
and 28% were off therapy for >5 yr. These findings support
the work of Seruga and Tannock, with data collected from
>1000 randomised patients indicating that IADT should be
regarded as standard therapy [11] for specific patient
groups. In 2007, Shaw et al. performed a meta-analysis of
1446 patients from international phase 2 studies and
concluded that the duration of biochemical remission after
a period of hormone therapy was a durable early indicator
of how rapidly androgen-independent PCa and death would
occur [12].
In our study, although not significant, more deaths from
any cancer occurred in the IHT arm, but more deaths from
CVD occurred in the continuous treatment arm. In contrast,
although there were no differences between study arms in
the domains of the QLQ-C30, side effects were generally less
commonly reported in the intermittent arm. Patients on
intermittent therapy experienced fewer sexual problems
and reported greater sexual activity than patients on
continuous therapy. During follow-up, although progres-
sively more patients in the intermittent arm were on
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 2 3 2 – 2 3 9238therapy and sexual activity decreased, sexual activity was
still significantly higher than among patients on continuous
therapy. Similar results have been reported in SEUG
9401 [2] and in other studies [6,13–15].
In protocol S9346 from Hussein et al. [3], IADT was
proven to be noninferior to continuous deprivation in
patients with extensive disease; however, intermittent
therapy was statistically inferior in patients with minimal
disease, suggesting that continuous therapy would be the
preferred treatment in this group. In contrast, there was no
difference between minimal disease and extended disease
in our trial.
5. Conclusions
From this study we can conclude that IHT should be
considered as the standard therapy for patients who are
not suitable for definitive therapy with advanced PCa
because IHT is noninferior to continuous therapy with
regard to OS. In addition, IHT is associated with better
QoL (ie, sexual life) and lower costs for communities than
continuous therapy. This study also showed that an
induction period of 3 mo is adequate to sufficiently reduce
PSA levels. Based on results from SEUG 9401 [2] and 9901,
we can define an optimal candidate for intermittent
therapy as a patient with (1) M0, (2) T3, and (3) PSA
levels prior to induction therapy <100 ng/ml whose PSA
decreases to <4 ng/ml (preferably <1 ng/ml) after 3 mo of
induction therapy. Intermittent therapy is less likely to be
beneficial for patients with metastasis and bone hot spots,
with high initial PSA levels (>100 ng/ml), or with severe
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